logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Daiichi Sankyo Inc. drugs

    FiltersReset Filters
    5 results

    • datroway

      (Datopotamab Deruxtecan)
      Daiichi Sankyo Inc.
      Usage: DATROWAY is indicated for adult patients with unresectable or metastatic, hormone receptor-positive, HER2-negative breast cancer who have previously received endocrine-based therapy and chemotherapy.

    • enhertu

      (fam-trastuzumab deruxtecan-nxki)
      Daiichi Sankyo Inc.
      Usage: ENHERTU is indicated for treating adult patients with unresectable or metastatic HER2-positive breast cancer, HER2-low or HER2-ultralow breast cancer, HER2-mutant non-small cell lung cancer, advanced HER2-positive gastric cancer, and unresectable HER2-positive solid tumors, all following prior systemic therapies.

    • savaysa

      (EDOXABAN TOSYLATE)
      Daiichi Sankyo Inc.
      Usage: SAVAYSA is indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for treating deep vein thrombosis and pulmonary embolism after initial therapy with a parenteral anticoagulant. It should not be used in patients with CrCL > 95 mL/min.

    • vanflyta

      (QUIZARTINIB)
      Daiichi Sankyo Inc.
      Usage: VANFLYTA is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 ITD-positive. It is used in combination with chemotherapy for induction and consolidation, and as maintenance monotherapy post-consolidation. Not for use after allogeneic stem cell transplantation.

    • welchol - colesevelam hydrochloride tablet, film coated

      (Colesevelam Hydrochloride)
      Daiichi Sankyo Inc.